ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1042

Building LSU Uveitis Registry ( BLUR ) Study – a Review of an Academic Rheumatology Center’s Experience and Approach to Uveitis

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1400

cAMP Response Element Modulator (CREM)α Promotes PD-1- effector CD4+ T Cells in Psoriasis and Psoriatic Arthritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1202

Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis

RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

9:00AM-11:00AM: Abstract Number: 1167

Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score

Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1328

Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Abstract Number: 1172

Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma

Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1179

Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study

RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

9:00AM-11:00AM: Abstract Number: 1331

Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Abstract Number: 1108

Cartilage Biomarkers s-Coll2-1 and s-Coll2-1NO2 Are Associated with Knee Osteoarthritis MRI Features and Predict Disease Worsening

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1318

Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Abstract Number: 1411

CD8+ T Cell Subsets and Immune Checkpoint Profiles in Ankylosing Spondylitis Implicate Dysregulation of Cytotoxic T Lymphocytes (CTL)

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1321

Central Sensitization, Disease Perception and Obesity Should Be Taken into Account When Interpreting Disease Activity in Patients with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Abstract Number: 1358

Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1382

Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1071

Characteristics of Anti-Transcription Intermediary Factor 1-gamma Autoantibody Positive Dermatomyositis Patients in Singapore

Muscle Biology, Myositis & Myopathies Poster

«Previous Page
1
…
3
4
5
6
7
…
37
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.